申请人:GlaxoSmithKline Intellectual Property (No. 2) Limited
公开号:US20160074394A1
公开(公告)日:2016-03-17
The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.
本发明涉及一种治疗T细胞介导的炎症免疫性疾病或T细胞介导的过敏性疾病的方法,包括向需要治疗的人类施用一种有效量的抑制EZH2和/或EZH1的化合物或其药学可接受的盐。